Cetuximab for the Treatment of Colorectal Cancer

Derek J. Jonker, Chris J. O’Callaghan, Christos S. Karapetis, +10

New England Journal of Medicine

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, +153

The Lancet

Pembrolizumab Versus PaclitaxelGastrointestinal OncologyMedicineGastroenterologySurgery +5

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, +20

JAMA

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Eric Van Cutsem, Fernando Rivera, Scott Berry, +8

Annals of Oncology

OncologyFirst-line BevacizumabGastrointestinal OncologyMedicineColorectal Cancer +8

American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer

Jeffrey Peppercorn, Thomas J. Smith, Paul R. Helft, +6

Journal of Clinical Oncology

Family MedicineQuality Of LifeCancer ManagementAmerican SocietyCancer Education +17

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez, +219

The Lancet Oncology

Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor +6

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer

Eric X. Chen, Derek J. Jonker, Jonathan M. Loree, +18

JAMA Oncology

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo, +138

The Lancet Oncology

First-line TherapyGastrointestinal OncologyMedicinePathologyMetastatic Gastric +4

Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group

Christina M. Canil, Malcolm J. Moore, Eric Winquist, +10

Journal of Clinical Oncology

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

Fred Saad, Sébastien J. Hotte, Scott North, +9

Clinical Cancer Research